Partnering

Partnering

Autifony will seek strategic partners for disease areas where significant resources are required for the later stages of development and commercialisation.

Autifony is interested in discussing specific in-licensing opportunities at the preclinical or early clinical stages in hearing disorders or in CNS that address significant unmet medical needs, on a case by case basis.

Related News

18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
15Mar

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq 
Autifony Therapeutic  @AutifonyLtd
RT @BIODeutschland:Boehringer Ingelheim & Autifony Therapeutics collaborate on a novel therapeutic approach to a range of CNS disorder… https://t.co/sIz3B7CkOe 

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image